Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCARCE: Atezolizumab + mDCF in Advanced Anal Carcinoma
NCT03519295Phase 2Completed
- Sponsor
- GERCOR
- Start
- Jul 2018
- Primary completion
- Feb 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in anal canal squamous cell carcinoma (SCCA) (2 arms), sponsored by GERCOR. Primary endpoint: Progression-Free Survival Rate at 12 months. Started Jul 2018; status: completed.
02
Drugs
atezolizumab
03
Conditions
anal canal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on NCT03519295.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519295.